Overcoming Disaster: What Biotechs Do When A Lead Asset Fails
Executive Summary
Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.
You may also be interested in...
Financings Of The Fortnight: Haircuts And Postponements Increasing As IPO Burst Slows Down
The IPO boom of 2013 is showing signs of slowing, while class of 2012 companies are seeing stock prices decline. Plus news on recent financings by Relypsa, Synta Pharmaceuticals, ArGEN-X and Karyopharm Therapeutics.
With Kolltan, Kinase Veteran Schlessinger Turns To Antibodies
Joseph Schlessinger’s insights into receptor tyrosine kinases (RTKs) led to small-molecule treatments and huge success at Sugen and Plexxikon. Schlessinger’s latest venture, Kolltan Pharmaceuticals, had little trouble raising $75 million, but powering up a pipeline of antibodies to target novel RTKs has proven more challenging.
AstraZeneca Opts Out Of Targacept Schizophrenia Program
Targacept says it will continue to develop its schizophrenia drug, even though AstraZeneca has opted not to move forward.